Abgenix to Receive Milestone Payment from Amgen for Advancement of Antibody Candidate from Technology Licensing Agreement
Abgenix, Inc. announced that it will receive a milestone payment from Amgen triggered by the advancement of AMG 162, a fully human antibody created using Abgenix's proprietary XenoMouse(R) technology, into a pivotal clinical trial. This is one of seven antibodies derived from XenoMouse technology that are currently in clinical trials by Abgenix and its various partners, and the first product candidate from Abgenix's technology out-licensing program to move into the pivotal phase of development.
"We are delighted with this news which reinforces the potential of our technology licensing program to contribute to a future stream of revenue," said Ray Withy, Ph.D., president and chief executive officer of Abgenix. "We believe that the achievement of this milestone also highlights the applicability of our XenoMouse technology in a variety of therapeutic applications."
Abgenix entered into an agreement with Amgen in April 1999 whereby Abgenix granted to Amgen a license to Abgenix's antibody generation technology. Amgen is responsible for product development and commercialization of any products developed through the collaboration. Abgenix may receive milestone payments and royalties of any future product sales.
Abgenix and Amgen have a separate co-development agreement for panitumumab, an EGFr inhibiting fully human monoclonal antibody that is currently in pivotal trials as a third line monotherapy for colorectal cancer
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous